Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlotte Becker

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Clinical Chemistry and Laboratory Medicine|June 22, 2012
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responsesDavid Ulmert, Andrew J Vickers, Howard I Scher, et al.
Cancer|March 26, 2010
Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, SwedenAndrew J Vickers, Angel M Cronin, Gunnar Aus, et al.
The Prostate|January 9, 2003
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancerAlexander Haese, Markus Graefen, Charlotte Becker, et al.
Molecular & Cellular Proteomics : MCP|August 5, 2010
Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assaysJochen M Schwenk, Ulrika Igel, Maja Neiman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened populationDavid Ulmert, Angel M Serio, Matthew F O'Brien, et al.
BMC Medicine|February 19, 2008
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control studyDavid Ulmert, Angel M Cronin, Thomas Björk, et al.
International Journal of Cancer|September 10, 2005
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serumThomas Steuber, Andrew J Vickers, Alexander Haese, et al.
Nature Neuroscience|April 24, 2026
Transcriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivoMeilin Fernandez Garcia, Kayla Retallick-Townsley, April Pruitt, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Clinical Chemistry and Laboratory Medicine|June 22, 2012
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responsesDavid Ulmert, Andrew J Vickers, Howard I Scher, et al.
Cancer|March 26, 2010
Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, SwedenAndrew J Vickers, Angel M Cronin, Gunnar Aus, et al.
The Prostate|January 9, 2003
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancerAlexander Haese, Markus Graefen, Charlotte Becker, et al.
Molecular & Cellular Proteomics : MCP|August 5, 2010
Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assaysJochen M Schwenk, Ulrika Igel, Maja Neiman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened populationDavid Ulmert, Angel M Serio, Matthew F O'Brien, et al.
BMC Medicine|February 19, 2008
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control studyDavid Ulmert, Angel M Cronin, Thomas Björk, et al.
International Journal of Cancer|September 10, 2005
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serumThomas Steuber, Andrew J Vickers, Alexander Haese, et al.
Nature Neuroscience|April 24, 2026
Transcriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivoMeilin Fernandez Garcia, Kayla Retallick-Townsley, April Pruitt, et al.
Pageof 4